Section 10-16-124.7 - Opioid analgesics with abuse-deterrent properties - study - definitions(1) The governor shall direct the Colorado consortium for prescription drug abuse prevention to study the barriers to the use of abuse-deterrent opioid analgesic drug products as a way to reduce abuse and diversion of opioid drug products. On or before January 15, 2017, the consortium shall report its findings to the public health care and human services committee and the health, insurance, and environment committee of the house of representatives and the health and human services committee of the senate, or their successor committees.(2) Moneys from the general fund shall not be used for the implementation of this section.(3) As used in this section: (a) "Abuse-deterrent opioid analgesic drug product" means a brand or generic opioid analgesic drug product approved by the FDA with abuse-deterrence labeling claims that indicate that the drug product is expected to result in a meaningful reduction in abuse.(b) "Opioid analgesic drug product" means a drug product in the opioid analgesic drug class prescribed to treat moderate to severe pain or other conditions, whether in immediate release or extended release or long-acting form, that may be combined with other drug substances to form a single drug product or dosage form.Amended by 2022 Ch. 126,§4, eff. 8/10/2022.Added by 2015 Ch. 175,§1, eff. 5/11/2015.L. 2015: Entire section added, (HB 15-1214), ch. 175, p. 570, § 1, effective May 11. 2022 Ch. 126, was passed without a safety clause. See Colo. Const. art. V, § 1(3).